Abbott named industry leader for responsible and sustainable business for three consecutive years on the Dow Jones Sustainability Index (DJSI)

AbbottFor the third consecutive year, Abbott (NYSE: ABT) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate responsibility and sustainability. As the Industry Group Leader in Health Care Equipment & Services, Abbott is the only U.S.-based company of the 24 companies recognized for leading their respective industry groups. The DJSI leaders are chosen from among 3,400 of the largest companies worldwide, including companies in developed and emerging markets. This is the 11th consecutive year that Abbott has been recognized for sustainability leadership through its inclusion on the DJSI, including both the Dow Jones Sustainability World Index and North America Index.

"Our purpose at Abbott is to help people live the best and fullest lives they can," said Miles D. White, chairman and chief executive officer, Abbott. "It all comes down to keeping our promise, by striving to advance human health and happiness in all we do and by approaching every challenge with utmost respect and sensitivity to our world and its people."

In addition to being named a broader Industry Group Leader, Abbott also was the leader in its specific DJSI industry sector, Health Care Equipment & Supplies. Abbott earned the highest industry scores across all three areas of overall economic, environmental and social performance. The company's score of 88 was more than double the average score of 39 for other companies in the industry. Abbott's leading position was strengthened in 2015; the company's score increased five points from 83 to 88, compared to a two-point average decrease across the industry.

Abbott also achieved the top industry scores in 15 of DJSI's 23 specific economic, environmental and social criteria, including innovation management; strategy to improve access to drugs or products; operational eco-efficiency; corporate governance; supply chain management; health outcome contribution; human capital development; labor practice indicators and human rights; talent attraction and retention; stakeholder engagement; customer relationship management; risk and crisis management; tax strategy; bioethics; and corporate citizenship and philanthropy.

About Abbott's approach to citizenship
At Abbott, we see tremendous potential to make life better. This idea is at the core of our approach to global citizenship - creating a more responsible, sustainable and inclusive business that builds better lives and stronger communities around the world.

We focus on three priority areas that are most important for our business and the many people we serve: delivering product excellence, improving access and safeguarding the environment. By applying our science, products and expertise in these three areas, we're working to maximize the promise of human potential, around the world.

In addition to being included in the Dow Jones Sustainability Index for 11 years, Abbott has been named one of the 100 Best Corporate Citizens by Corporate Responsibility magazine for seven consecutive years.

About the Dow Jones Sustainability Index (DJSI)
Launched in 1999, the Dow Jones Sustainability Index (DJSI) is the first global index to track the leading sustainability-driven companies worldwide based on an analysis of financially material environmental, social and governance factors. The Dow Jones Sustainability Indices are maintained collaboratively by S&P Dow Jones Indices and RobecoSAM, the investment specialist focused exclusively on Sustainability Investing. RobecoSAM invited the world's largest 3,400 companies from developed and emerging markets to take part in its annual Corporate Sustainability Assessment.

About Abbott
At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 73,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

MSD Innovation Factory is looking for digital solu…

MSD is looking for innovators to solve 7 health-related challenges. One of them seeks to support anaesthesiologists with their continuous education (e.g. at the operation...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]